ProKidney Corp - Class A

Research ProKidney Corp - Class A (PROK) on Bullrun: market cap USD 387.83M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerPROK
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 387.83M
• Financial periodFY2025
• RevenueUSD 893.00K
• Revenue growth1075.0%
• Net income-USD 68.99M
• Free cash flow-USD 135.31M

Valuation Snapshot

latest market cap is USD 387.83M.

About ProKidney Corp - Class A

ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes.

Frequently asked questions

What is ProKidney Corp - Class A's market cap?

ProKidney Corp - Class A's market capitalization is USD 387.83M.

What does ProKidney Corp - Class A do?

ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States.